CTLA4 and hypophysitis: A meta-analysis of 38 studies reported that patients who received anti-PD1 drugs had 0.29 less risk of developing any grade of hypophysitis than those who received ipilimumab(anti-CTLA4 drug), whereas the patients who received these two medications in combination had a 2.2 odds ratio to develop hypophysitis ( 26 ).